Myeloma Trial, Recruiting (NCT06698887)

Myeloma Trial, Recruiting NCT06698887 Sponsor: Bristol-Myers Squibb Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06698887 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must be 19 years of age or older
You must be a Korean participant who was newly diagnosed with multiple myeloma, did not respond well enough after a stem cell transplant using your own stem cells, and received a specific treatment called idecabtagene vicleucel (ide-cel) as part of a related clinical trial called KarMMa-9
You must be willing to read, understand, and sign a consent form agreeing to take part in this long-term follow-up study before any study-related checks begin

Who may not be able to join:

If you took part in the KarMMa-9 trial but do not agree to be followed up and monitored long-term as part of this Korean study, you would not be eligible
If it is not possible for you to receive the ide-cel treatment within 9 days after finishing a preparatory chemotherapy phase (called lymphodepleting chemotherapy), you may not be able to join — though your doctor and the study team would discuss your individual situation to decide (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06698887

Sponsor: Bristol-Myers Squibb

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

Trial contact: 855-907-3286

More information: https://clinicaltrials.gov/study/NCT06698887

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must be 19 years of age or older
You must be a Korean participant who was newly diagnosed with multiple myeloma, did not respond well enough after a stem cell transplant using your own stem cells, and received a specific treatment called idecabtagene vicleucel (ide-cel) as part of a related clinical trial called KarMMa-9
You must be willing to read, understand, and sign a consent form agreeing to take part in this long-term follow-up study before any study-related checks begin

Who may not be able to join:

If you took part in the KarMMa-9 trial but do not agree to be followed up and monitored long-term as part of this Korean study, you would not be eligible
If it is not possible for you to receive the ide-cel treatment within 9 days after finishing a preparatory chemotherapy phase (called lymphodepleting chemotherapy), you may not be able to join — though your doctor and the study team would discuss your individual situation to decide (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Bristol-Myers Squibb

Registry

ClinicalTrials.gov

Start date

11 September 2024

Est. completion

27 March 2031

Where this trial is recruiting

🇰🇷 South Korea

Primary endpoints

Participant adverse events; Number of participants with positive replication-competent lentivirus test results; Persistent vector sequence monitoring

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov